Medtronic's SelecrSecure pacing lead:
This article was originally published in Clinica
Executive Summary
Medtronic has received US approval to sell what it claims is the industry's first cardiac pacing lead designed to enable physicians to reach selected sites of the right side of the heart. The SelectSecure model 3830 lead is the world's thinnest bipolar lead, said the company, which has now introduced the product in the US. The product is unique in that it comprises a "lumenless design" that allows for flexibility and a smaller body size (4.1F), without sacrificing insulation thickness, the firm explained. A deflectable catheter is used to position the lead in the best locations of the right atrium or ventricle. The lead can be used with pacemakers, implantable cardioverter-defibrillators and cardiac resynchronisation therapy (CRT) devices.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.